Compare $GALT vs $USBC | Chartloom

Compare

$GALT vs $USBC

Galectin Therapeutics Inc · USBC Inc

GALT

Galectin Therapeutics Inc

USBC

USBC Inc

Compare $GALT vs $USBC

Comparing Galectin Therapeutics Inc and USBC Inc

GALTGalectin Therapeutics Inc

USBCUSBC Inc

GALTGalectin Therapeutics Inc

Market cap

$259M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-2.7%

52W performance

-16.9%

FCF yield

-6.1%

USBCUSBC Inc

Market cap

$198M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-22.2%

52W performance

-51.9%

FCF yield

-11.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GALT

USBC

Detailed metrics comparison

GALT

Galectin Therapeutics Inc

USBC

USBC Inc

Market Cap

GALT$259M

USBC$198M

Enterprise Value

GALT$384M

USBC$210M

Price

GALT$3.94

USBC$0.51

P/E Ratio

GALTN/A

USBCN/A

P/S Ratio

GALT0.00x

USBC0.00x

EV/Sales

GALT0.00x

USBC0.00x

EV/EBITDA

GALT0.00x

USBC0.00x

P/B Ratio

GALT150.12x

USBC4.46x

P/FCF Ratio

GALTN/A

USBCN/A

EV/FCF

GALT-24.16x

USBC-9.14x

PEG Ratio

GALTN/A

USBCN/A

Forward P/E (NTM)

GALTN/A

USBCN/A

Forward P/S (NTM)

GALTN/A

USBCN/A

Revenue (TTM)

GALT$0

USBC$0

Revenue Growth (YoY)

GALTN/A

USBCN/A

Forward Rev Growth

GALT0.0%

USBC0.0%

Gross Margin (TTM)

GALT0.0%

USBC0.0%

Operating Margin (TTM)

GALT0.0%

USBC0.0%

EBITDA Margin (TTM)

GALT0.0%

USBC0.0%

Net Margin (TTM)

GALT0.0%

USBC0.0%

FCF Margin (TTM)

GALTN/A

USBCN/A

Net Income (TTM)

GALT$-28M

USBC$-86M

FCF (TTM)

GALT$-16M

USBC$-23M

EPS (TTM)

GALT-$0.43

USBC-$0.22

ROE (TTM)

GALT-25862.0%

USBC-12093.0%

ROA (TTM)

GALT-17683.0%

USBC-9639.0%

ROIC (TTM)

GALT-11607.0%

USBC-11297.0%

Cash

GALT$13M

USBC$3M

Debt

GALT$138M

USBC$15M

Net Cash/Debt

GALT$-124M

USBC$-12M

Current Ratio (TTM)

GALT0.10x

USBC0.23x

Quick Ratio (TTM)

GALT0.09x

USBC0.20x

Debt/Equity (TTM)

GALT11.09x

USBC0.32x

Debt/Assets (TTM)

GALT0.0%

USBC0.0%

Interest Coverage (TTM)

GALTN/A

USBCN/A

Net Debt/EBITDA (TTM)

GALT0.00x

USBC0.00x

Beta

GALT0.50

USBC2.77

52W Performance

GALT-16.9%

USBC-51.9%

YTD Performance

GALT-2.7%

USBC-22.2%

% from 52W High

GALT-44.7%

USBC-60.5%

% from 52W Low

GALT94.6%

USBC78.7%

Asset Turnover (TTM)

GALT0.00x

USBC0.00x

FCF Yield (TTM)

GALT-6.1%

USBC-11.6%

Earnings Yield (TTM)

GALT-10.8%

USBC-43.5%

Dividend Yield (TTM)

GALTN/A

USBCN/A

Rule of 40

GALT0.0

USBC0.0

EV/GP/RG

GALTN/A

USBCN/A

Ticker research

View GALT research View USBC research

Metric	GALT Galectin Therapeutics Inc	USBC USBC Inc
Market & Valuation
Market Cap	$259M	$198M
Enterprise Value	$384M	$210M
Price	$3.94	$0.51
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	150.12x	4.46x
P/FCF Ratio	N/A	N/A
EV/FCF	-24.16x	-9.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-28M	$-86M
FCF (TTM)	$-16M	$-23M
EPS (TTM)	-$0.43	-$0.22
ROE (TTM)	-25862.0%	-12093.0%
ROA (TTM)	-17683.0%	-9639.0%
ROIC (TTM)	-11607.0%	-11297.0%
Financial Health
Cash	$13M	$3M
Debt	$138M	$15M
Net Cash/Debt	$-124M	$-12M
Current Ratio (TTM)	0.10x	0.23x
Quick Ratio (TTM)	0.09x	0.20x
Debt/Equity (TTM)	11.09x	0.32x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.50	2.77
52W Performance	-16.9%	-51.9%
YTD Performance	-2.7%	-22.2%
% from 52W High	-44.7%	-60.5%
% from 52W Low	94.6%	78.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-6.1%	-11.6%
Earnings Yield (TTM)	-10.8%	-43.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View GALT research	View USBC research

Valuation

P/S Ratio

GALT

0.00x

USBC

0.00x

EV/FCF

GALT

-24.16x

USBC

-9.14x

Growth & revenue

Forward Revenue Growth

GALT

0.0%

USBC

0.0%

Profitability & performance

Gross Margin

GALT

0.0%

USBC

0.0%

ROE

USBC

-12093.0%

GALT

-25862.0%

FCF Yield %

GALT

-6.1%

USBC

-11.6%

52-Week Performance

GALT

-16.9%

USBC

-51.9%

Detailed metrics comparison

GALT

Galectin Therapeutics Inc

USBC

USBC Inc

Market Cap

GALT$259M

USBC$198M

Enterprise Value

GALT$384M

USBC$210M

Price

GALT$3.94

USBC$0.51

P/E Ratio

GALTN/A

USBCN/A

P/S Ratio

GALT0.00x

USBC0.00x

EV/Sales

GALT0.00x

USBC0.00x

EV/EBITDA

GALT0.00x

USBC0.00x

P/B Ratio

GALT150.12x

USBC4.46x

P/FCF Ratio

GALTN/A

USBCN/A

EV/FCF

GALT-24.16x

USBC-9.14x

PEG Ratio

GALTN/A

USBCN/A

Forward P/E (NTM)

GALTN/A

USBCN/A

Forward P/S (NTM)

GALTN/A

USBCN/A

Revenue (TTM)

GALT$0

USBC$0

Revenue Growth (YoY)

GALTN/A

USBCN/A

Forward Rev Growth

GALT0.0%

USBC0.0%

Gross Margin (TTM)

GALT0.0%

USBC0.0%

Operating Margin (TTM)

GALT0.0%

USBC0.0%

EBITDA Margin (TTM)

GALT0.0%

USBC0.0%

Net Margin (TTM)

GALT0.0%

USBC0.0%

FCF Margin (TTM)

GALTN/A

USBCN/A

Net Income (TTM)

GALT$-28M

USBC$-86M

FCF (TTM)

GALT$-16M

USBC$-23M

EPS (TTM)

GALT-$0.43

USBC-$0.22

ROE (TTM)

GALT-25862.0%

USBC-12093.0%

ROA (TTM)

GALT-17683.0%

USBC-9639.0%

ROIC (TTM)

GALT-11607.0%

USBC-11297.0%

Cash

GALT$13M

USBC$3M

Debt

GALT$138M

USBC$15M

Net Cash/Debt

GALT$-124M

USBC$-12M

Current Ratio (TTM)

GALT0.10x

USBC0.23x

Quick Ratio (TTM)

GALT0.09x

USBC0.20x

Debt/Equity (TTM)

GALT11.09x

USBC0.32x

Debt/Assets (TTM)

GALT0.0%

USBC0.0%

Interest Coverage (TTM)

GALTN/A

USBCN/A

Net Debt/EBITDA (TTM)

GALT0.00x

USBC0.00x

Beta

GALT0.50

USBC2.77

52W Performance

GALT-16.9%

USBC-51.9%

YTD Performance

GALT-2.7%

USBC-22.2%

% from 52W High

GALT-44.7%

USBC-60.5%

% from 52W Low

GALT94.6%

USBC78.7%

Asset Turnover (TTM)

GALT0.00x

USBC0.00x

FCF Yield (TTM)

GALT-6.1%

USBC-11.6%

Earnings Yield (TTM)

GALT-10.8%

USBC-43.5%

Dividend Yield (TTM)

GALTN/A

USBCN/A

Rule of 40

GALT0.0

USBC0.0

EV/GP/RG

GALTN/A

USBCN/A

Ticker research

View GALT research View USBC research

Metric	GALT Galectin Therapeutics Inc	USBC USBC Inc
Market & Valuation
Market Cap	$259M	$198M
Enterprise Value	$384M	$210M
Price	$3.94	$0.51
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	150.12x	4.46x
P/FCF Ratio	N/A	N/A
EV/FCF	-24.16x	-9.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-28M	$-86M
FCF (TTM)	$-16M	$-23M
EPS (TTM)	-$0.43	-$0.22
ROE (TTM)	-25862.0%	-12093.0%
ROA (TTM)	-17683.0%	-9639.0%
ROIC (TTM)	-11607.0%	-11297.0%
Financial Health
Cash	$13M	$3M
Debt	$138M	$15M
Net Cash/Debt	$-124M	$-12M
Current Ratio (TTM)	0.10x	0.23x
Quick Ratio (TTM)	0.09x	0.20x
Debt/Equity (TTM)	11.09x	0.32x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.50	2.77
52W Performance	-16.9%	-51.9%
YTD Performance	-2.7%	-22.2%
% from 52W High	-44.7%	-60.5%
% from 52W Low	94.6%	78.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-6.1%	-11.6%
Earnings Yield (TTM)	-10.8%	-43.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View GALT research	View USBC research